IP Library Granted Patent US 8,673,896
Granted Patent B2
US 8,673,896 · App. 13/092,332 · Granted Mar 18, 2014

Benzodiazepine and pyridodiazepine derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,673,896
App. No.
13/092,332
Granted
Mar 18, 2014
Kind
B2
Abstract

The present application relates to benzodiazepine and pyridodiazepine derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , X 1 , Y 1 , Y 2 , and Y 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Claims (257)

1. A compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein

R 1 is selected from the group consisting of alkylcarbonyl, haloalkyl, G 1 , —(CR 4a R 5a ) m -G 1 , —C(O)-G 1 , —S(O) 2 G 1 , —C(O)OR 6 and —C(O)NR 7 R 8 ; wherein R 1 is other than alkylcarbonyl, or haloalkyl when one of Y 1 or Y 2 is CH 2 and the other is NR 9 ;

R 2 , R 3 , and R 4 are each independently hydrogen, alkyl, alkenyl, alkynyl, halogen, cyano, —NO 2 , —OR 1a , —S(O) 2 R 2a , —C(O)OR 1a , or haloalkyl;

R 5 is hydrogen;

R 6 is alkyl or —(CR 4a R 5a ) m -G 1 ;

R 7 and R 8 are independently hydrogen, alkyl, G 1 , or —(CR 4a R 5a ) m -G 1 ;

R 9 is hydrogen or alkyl;

R 1a , at each occurrence, is independently hydrogen, alkyl, haloalkyl, or —(CR 4a R 5a ) m -G 1 ;

R 2a , at each occurrence, is independently alkyl, haloalkyl, or G 1 ;

R 4a and R 5a , at each occurrence, are each independently hydrogen, halogen, alkyl, or haloalkyl, or R 4a and R 5a together with the carbon to which they are attached form a cycloalkyl;

R 1b , at each occurrence, is independently hydrogen, alkyl, or haloalkyl;

R 2b , at each occurrence, is independently alkyl, cyanoalkyl or haloalkyl;

G 1 , at each occurrence, is independently aryl or heteroaryl, wherein each G 1 is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, alkenyl, halogen, cyano, —NO 2 , —OR 1b , —S(O) 2 R 2b , —C(O)OR 1b , —(CR 4a R 5a ) m —N(R 1b ) 2 , and haloalkyl;

G 2 , at each occurrence, is independently cycloalkyl or heterocycle, wherein each G 2 is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, alkenyl, halogen, cyano, —NO 2 , —OR 1b , —S(O) 2 R 2b , —C(O)OR 1b , —C(O)R 2b , —C(O)N(R 1b ) 2 , haloalkyl, and oxo;

m, at each occurrence, is independently 1, 2, 3, 4, or 5;

X 1 is CR 5 ;

Y 1 is CH 2 ;

Y 2 is selected from the group consisting of NR 9 , N-G 1 , N—(CR 4a R 5a ) m -G 1 , N + -[(CR 4a R 5a ) m -G 1 ] 2 , NC(O)—(CR 4a R 5a ) m -G 1 , NC(O)—CH═CH-G 1 , NC(O)-G 1 , NC(O)-G 2 -G 1 , N-G 2 , N—(CR 4a R 5a ) m -G 2 , NC(O)—(CR 4a R 5a ) m -G 2 , and NC(O)-G 2 ; wherein

W 1 is NHC(O)G 1 or —O—(CR 4a R 5a ) m —R 1b ;

and

Y 3 is C(O).

2. The compound of claim 1 , wherein R 1 is selected from the group consisting of —(CR 4a R 5a ) m -G 1 and —C(O)OR 6 ; and

Y 2 is NR 9 , N—(CR 4a R 5a ) m -G 1 or N—(CR 4a R 5a ) m -G 2 .

3. A compound of formula (I)

or a pharmaceutically acceptable salt thereof, wherein

R 1 is selected from the group consisting of alkylcarbonyl, haloalkyl, G 1 , —(CR 4a R 5a ) m -G 1 , —C(O)-G 1 , —S(O) 2 G 1 , —C(O)OR 6 and —C(O)NR 7 R 8 ; wherein R 1 is other than alkylcarbonyl, or haloalkyl when one of Y 1 or Y 2 is CH 2 and the other is NR 9 ;

R 2 , R 3 , and R 4 are each independently hydrogen, alkyl, alkenyl, alkenyl, halogen, cyano, —NO 2 , —OR 1a , —S(O) 2 R 2a , —C(O)OR 1a , or haloalkyl;

R 5 is hydrogen;

R 6 is alkyl or —(CR 4a R 5a ) m -G 1 ;

R 7 and R 8 are independently hydrogen, alkyl, G 1 , or —(CR 4a R 5a ) m -G 1 ;

R 9 is hydrogen or alkyl;

R 1a , at each occurrence, is independently hydrogen, alkyl, haloalkyl, or —(CR 4a R 5a ) m -G 1 ;

R 2a , at each occurrence, is independently alkyl, haloalkyl, or G 1 ;

R 4a and R 5a , at each occurrence, are each independently hydrogen, halogen, alkyl, or haloalkyl, or R 4a and R 5a together with the carbon to which they are attached form a cycloalkyl;

R 1b , at each occurrence, is independently hydrogen, alkyl, or haloalkyl;

R 2b , at each occurrence, is independently alkyl, cyanoalkyl or haloalkyl;

G 1 , at each occurrence, is independently aryl or heteroaryl, wherein each G 1 is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, alkenyl, halogen, cyano, —NO 2 , —OR 1b , —S(O) 2 R 2b , —C(O)OR 1b , —(CR 4a R 5a ) m —N(R 1b ) 2 , and haloalkyl;

G 2 , at each occurrence, is independently cycloalkyl or heterocycle, wherein each G 2 is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, alkenyl, halogen, cyano, —NO 2 , —OR 1b , —S(O) 2 R 2b , —C(O)OR 1b , —C(O)R 2b , —C(O)N(R 1b ) 2 , haloalkyl, and oxo;

m, at each occurrence, is independently 1, 2, 3, 4, or 5;

X 1 is CR 5 ;

Y 1 is CH 2 ;

Y 2 is selected from the group consisting of NR 9 , N-G 1 , N—(CR 4a R 5a ) m -G 1 , N + -[(CR 4a R 5a ) m -G 1 ] 2 , NC(O)—R 2b , NC(O)—(CR 4a R 5a ) m -G 1 ; NC(O)—(CR 4a R 5a ) m —W 1 , NC(O)—CH═CH-G 1 , NC(O)-G 1 , NC(O)-G 2 -G 1 , N-G 2 , N-G 2 -C(O)-G 1 , N—(CR 4a R 5a ) m -G 2 , NC(O)—(CR 4a R 5a ) m -G 2 , NC(O)-G 2 , NC(O)NH—W 3 , NC(O)N(R 2b )—W 3 , and NC(O)N(R 1b )—(CR 4a R 5a ) m —W 2 ; wherein

W 1 is NHC(O)G 1 or —O—(CR 4a R 5a ) m —R 1b ;

W 2 is G 1 , G 2 , N(R 1b ) 2 , R 1b , or —O—(CR 4a R 5a ) m —R 1b ;

W 3 is R 1b , G 1 or G 2 ; and

Y 3 is CH 2 .

4. The compound of claim 3 , wherein R 1 is —(CR 4a R 5a ) m -G 1 ; and Y 2 is NR 9 .

5. The compound of claim 3 , wherein R 1 is —(CR 4a R 5a ) m -G 1 or —C(O)OR 6 ;

Y 2 is N—(CR 4a R 5a ) m -G 1 , N—(CR 4a R 5a ) m -G 2 , or N + -[(CR 4a R 5a ) m -G 1 ] 2 ; and

m, at each occurrence, is independently 1, 2, or 3.

6. The compound of claim 3 , wherein R 1 is —(CR 4a R 5a ) m -G 1 ;

Y 2 is N-G 1 or N-G 2 -C(O)-G 1 ; and

m is independently 1, 2, or 3.

7. The compound of claim 3 , wherein R 1 is alkylcarbonyl, G 1 , —(CR 4a R 5a ) m -G 1 , —C(O)-G 1 , or —S(O) 2 G 1 ; and

Y 2 is NC(O)—(CR 4a R 5a ) m -G 1 , NC(O)—CH═CH-G 1 , NC(O)-G 1 , NC(O)-G 2 -G 1 , NC(O)—(CR 4a R 5a ) m -G 2 , NC(O)—(CR 4a R 5a ) m —W 1 , NC(O)—R 2b or NC(O)-G 2 .

8. The compound of claim 3 , wherein R 1 is G 1 , —(CR 4a R 5a ) m -G 1 , —C(O)-G 1 , or —S(O) 2 G 1 ; and

Y 2 is NC(O)NH—W 3 , NC(O)N(R 2b )—W 3 , or NC(O)N(R 1b )—(CR 4a R 5a ) m —W 2 .

9. A compound of formula (I)

or a pharmaceutically acceptable salt thereof, wherein

R 1 is selected from the group consisting of alkylcarbonyl, haloalkyl, G 1 , —(CR 4a R 5a ) m -G 1 , —C(O)-G 1 , —S(O) 2 G 1 , —C(O)OR 6 and —C(O)NR 7 R 8 ; wherein R 1 is other than alkylcarbonyl, or haloalkyl when one of Y 1 or Y 2 is CH 2 and the other is NR 9 ;

R 2 , R 3 , R 4 , and R 5 are each independently hydrogen, alkyl, alkenyl, alkenyl, halogen, cyano, —NO 2 , —OR 1a , —S(O) 2 R 2a , —C(O)OR 1a , or haloalkyl;

R 6 is alkyl or —(CR 4a R 5a ) m -G 1 ;

R 7 and R 8 are independently hydrogen, alkyl, G 1 , or —(CR 4a R 5a ) m -G 1 ;

R 9 is hydrogen or alkyl;

R 1a , at each occurrence, is independently hydrogen, alkyl, haloalkyl, or —(CR 4a R 5a ) m -G 1 ;

R 2a , at each occurrence, is independently alkyl, haloalkyl, or G 1 ;

R 4a and R 5a , at each occurrence, are each independently hydrogen, halogen, alkyl, or haloalkyl, or R 4a and R 5a together with the carbon to which they are attached form a cycloalkyl;

R 1b , at each occurrence, is independently hydrogen, alkyl, or haloalkyl;

R 2b , at each occurrence, is independently alkyl, cyanoalkyl or haloalkyl;

G 1 , at each occurrence, is independently aryl or heteroaryl, wherein each G 1 is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, alkenyl, halogen, cyano, —NO 2 , —OR 1b , —S(O) 2 R 2b , —C(O)OR 1b , —(CR 4a R 5a ) m —N(R 1b ) 2 , and haloalkyl;

G 2 , at each occurrence, is independently cycloalkyl or heterocycle, wherein each G 2 is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, alkenyl, halogen, cyano, —NO 2 , —OR 1b , —S(O) 2 R 2b , —C(O)OR 1b , —C(O)R 2b , —C(O)N(R 1b ) 2 , haloalkyl, and oxo;

m, at each occurrence, is independently 1, 2, 3, 4, or 5;

X 1 is N or CR 5 ;

Y 1 is selected from the group consisting of NR 9 , N-G 1 , N—(CR 4a R 5a ) m -G 1 , N + -[(CR 4a R 5a ) m -G 1 ] 2 , NC(O)—R 2b , NC(O)—(CR 4a R 5a ) m -G 1 ; NC(O)—(CR 4a R 5a ) m —W 1 , NC(O)—CH═CH-G 1 , NC(O)-G 1 , NC(O)-G 2 -G 1 , N-G 2 , N-G 2 -C(O)-G 1 , N—(CR 4a R 5a ) m -G 2 , NC(O)—(CR 4a R 5a ) m -G 2 , NC(O)-G 2 , NC(O)NH—W 3 , NC(O)N(R 2b )—W 3 , and NC(O)N(R 1b )—(CR 4a R 5a ) m —W 2 ; wherein

W 1 is NHC(O)G 1 or —O—(CR 4a R 5a ) m —R 1b ;

W 2 is G 1 , G 2 , N(R 1b ) 2 , R 1b , or —O—(CR 4a R 5a ) m —R 1b ;

W 3 is R 1b , G 1 or G 2 ;

Y 2 is CH 2 ; and

Y 3 is CH 2 .

10. The compound of claim 9 , wherein R 1 is —(CR 4a R 5a ) m -G 1 ; and

Y 1 is NR 9 .

11. The compound of claim 9 , wherein R 1 is —(CR 4a R 5a ) m -G 1 or —C(O)-G 1 ; and

Y 1 is N—(CR 4a R 5a ) m -G 1 , or N—(CR 4a R 5a ) m -G 2 .

12. The compound of claim 9 , wherein X 1 is CR 5 or N;

R 5 is hydrogen;

R 1 is —(CR 4a R 5a ) m -G 1 ; and

Y 1 is NC(O)—(CR 4a R 5a ) m -G 1 , NC(O)-G 1 , NC(O)—(CR 4a R 5a ) m -G 2 , or NC(O)-G 2 .

13. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

tert-butyl 5-oxo-1,2,4a,5,6,7-hexahydropyrazino[1,2-a][1,4]benzodiazepine-3(4H)-carboxylate;

3-(4-fluorobenzyl)-2,3,4,4a,6,7-hexahydropyrazino[1,2-a][1,4]benzodiazepin-5(1H)-one;

tert-butyl 6-(4-bromobenzyl)-5-oxo-1,2,4a,5,6,7-hexahydropyrazino[1,2-a][1,4]benzodiazepine-3(4H)-carboxylate; and

6-(4-bromobenzyl)-3-(4-fluorobenzyl)-2,3,4,4a,6,7-hexahydropyrazino[1,2-a][1,4]benzodiazepin-5 (1H)-one.

14. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 3 or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

16. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 9 or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

17. The compound according to claim 3 or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

3-benzyl-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(4-bromobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

1-(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)-2-phenylethanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(phenyl)methanone;

3,6,6-tribenzyl-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepin-6-ium;

3,6-dibenzyl-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-methyl-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(pyrimidin-2-yl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(4-fluorophenyl)methanone;

3-benzyl-6-(pyrazin-2-yl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(pyrazin-2-yl)methanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(1-phenylcyclopropyl)methanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(morpholin-4-yl)methanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)[trans-2-phenylcyclopropyl]methanone;

3-benzyl-6-(pyridin-2-yl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(4-fluorobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

(−)-3-benzyl-6-(4-bromobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

(+)-3-benzyl-6-(4-bromobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

(2E)-1-(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin6(7H)-yl)-3-phenylprop-2-en-1-one;

3-benzyl-6-[4-(trifluoromethyl)benzyl]-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(4-bromo-3-fluorobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(3,5-difluorobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(3,4-difluorobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(pyridin-3-ylmethyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(pyridin-2-ylmethyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(pyridin-4-ylmethyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(4-bromophenyl)methanone;

3-benzyl-6-[(6-methylpyridin-3-yl)methyl]-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(quinolin-3-ylmethyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-[(6-chloropyridin-3-yl)methyl]-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-{[6-(trifluoromethyl)pyridin-3-yl]methyl}-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(quinolin-4-ylmethyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(isoquinolin-4-ylmethyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-[(6-bromopyridin-3-yl)methyl]-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-(4-fluorobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-[(5-bromopyridin-2-yl)methyl]-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(4-iodobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

4-[(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)methyl]phenol;

6-(4-bromobenzyl)-3-(4-fluorobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

1-(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)-2-(6-chloropyridin-3-yl)ethanone;

(+)-(4aS)-6-(4-bromobenzyl)-3-(4-fluorobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

(−)-(4aR)-6-(4-bromobenzyl)-3-(4-fluorobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-[2-(6-chloropyridin-3-yl)ethyl]-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

tert-butyl 6-(4-bromobenzyl)-1,2,4a,5,6,7-hexahydropyrazino[1,2-a][1,4]benzodiazepine-3(4H)-carboxylate;

[3-(4-fluorobenzyl)-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl](morpholin-4-yl)methanone;

(3-benzoyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)yl)(morpholin-4-yl)methanone;

morpholin-4-yl[3-(pyrimidin-2-yl)-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl]methanone;

morpholin-4-yl[3-(phenylsulfonyl)-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl]methanone;

[3-(4-chlorophenyl)-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl](morpholin-4-yl)methanone;

1-[6-(morpholin-4-ylcarbonyl)-1,2,4a,5,6,7-hexahydropyrazino[1,2-a][1,4]benzodiazepin-3(4H)-yl]ethanone;

1-{4-[(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)carbonyl]piperidin-1-yl}ethanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(1H-pyrazol-4-yl)methanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(1H-pyrazol-5-yl)methanone;

1-(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)-2-(morpholin-4-yl)ethanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(1,3-thiazol-4-yl)methanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(1,3-thiazol-5-yl)methanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(1,2-oxazol-5-yl)methanone;

1-(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)-3-(pyrrolidin-1-yl)propan-1-one;

1-(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)-2-cyclopropylethanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(1H-pyrrol-2-yl)methanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(3-furyl)methanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(1,2,5-trimethyl-1H-pyrrol-3-yl)methanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(2,5-dimethyl-1H-pyrrol-3-yl)methanone;

1-[(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)carbonyl]cyclopropanecarboxamide;

1-(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)-2-(pyridin-3-yl)ethanone;

N-[2-(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)-2-oxoethyl]-2-furamide;

1-(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)-2-methylpropan-1-one;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(3,5-dimethyl-1,2-oxazol-4-yl)methanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(5-methylpyrazin-2-yl)methanone;

1-(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)-2-(4-methylpiperazin-1-yl)ethanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(2-furyl)methanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(1-methyl-1H-pyrrol-2-yl)methanone;

1-(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)propan-1-one;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(pyridin-4-yl)methanone;

1-(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)butan-1-one;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(tetrahydrofuran-3-yl)methanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(pyridin-3-yl)methanone;

1-(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)-3-(piperidin-1-yl)propan-1-one;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(cyclopropyl)methanone;

1-(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)-2-ethoxyethanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(1-methylcyclopropyl)methanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(cyclobutyl)methanone;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(2-methylcyclopropyl)methanone;

1-(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)-3,3,3-trifluoropropan-1-one;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(tetrahydrofuran-2-yl)methanone;

3-benzyl-6-(4-methoxy-3-methylbenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-[(4,5-dimethyl-2-furyl)methyl]-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(4-ethoxybenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-[(5-methyl-2-thienyl)methyl]-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(4-bromobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(2-naphthylmethyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(cyclopentylmethyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(quinolin-2-ylmethyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-[(5-ethyl-2-furyl)methyl]-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

4-[(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)methyl]benzonitrile;

3-benzyl-6-butyl-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(4-chlorobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(2-methylbenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(2-bromobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(2-methoxybenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(4-methoxybenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(3-methoxybenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(3-bromobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(4-methylbenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(1-naphthylmethyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(2-chlorobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(3-chlorobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(2,2-dimethylpropyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-[(3-methyl-2-thienyl)methyl]-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(3-methylbutyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(cyclohexylmethyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-(3-methylbenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-[(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)methyl]benzonitrile;

3-benzyl-6-(2-thienylmethyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-6-isobutyl-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine;

3-benzyl-N-(2-methoxyethyl)-N-methyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N-[2-(pyridin-3-yl)ethyl]-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N-[2-(pyridin-2-yl)ethyl]-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N-[2-(pyridin-4-yl)ethyl]-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N-(2-cyanoethyl)-N-cyclopropyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

[4-(2-aminoethyl)-1H-imidazol-1-yl](3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)methanone;

3-benzyl-N-(pyridin-4-ylmethyl)-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N-[(5-methyl-2-furyl)methyl]-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N-ethyl-N-(2-methoxyethyl)-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N,N-diethyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N-(1,3-thiazol-2-yl)-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N-(cyclopropylmethyl)-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(4-isopropylpiperazin-1-yl)methanone;

3-benzyl-N-isobutyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N-(pyridin-3-ylmethyl)-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N-[3-(dimethylamino)propyl]-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N-butyl-N-(cyanomethyl)-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N-(3-methoxypropyl)-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N-(2-methoxyethyl)-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N-(pyridin-2-ylmethyl)-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N-cyclobutyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide;

3-benzyl-N-methyl-N-propyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine-6(7H)-carboxamide; and

(3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(piperidin-1-yl)methanone.

18. The compound according to claim 9 or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

3-benzyl-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine;

1-(3-benzyl-2,3,4,4a,5,6-hexahydropyrazino[1,2-a][1,5]benzodiazepin-7(1H)-yl)-2-(4-chlorophenyl)ethanone;

(3-benzyl-2,3,4,4a,5,6-hexahydropyrazino[1,2-a][1,5]benzodiazepin7(1H)-yl)(4-bromophenyl)methanone;

(3-benzyl-2,3,4,4a,5,6-hexahydropyrazino[1,2-a][1,5]benzodiazepin-7(1H)-yl)(pyridin-4-yl)methanone;

3-benzyl-7-[2-(4-chlorophenyl)ethyl]-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine;

3,7-dibenzyl-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine;

3-benzyl-7-(4-bromobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine;

3-benzyl-7-(pyridin-4-ylmethyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine;

3-benzyl-7-methyl-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine;

9-benzyl-5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine;

1-(9-benzyl-7,7a,8,9,10,11-hexahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepin-5(6H)-yl)-2-(4-chlorophenyl)ethanone;

9-benzyl-5-[2-(4-chlorophenyl)ethyl]-5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine;

9-benzyl-5-methyl-5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine;

(9-benzyl-7,7a,8,9,10,11-hexahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepin-5(6H)-yl)(2,2,3,3-tetramethylcyclopropyl)methanone;

9-benzyl-5-[(2,2,3,3-tetramethylcyclopropyl)methyl]-5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine;

5-(cyclopropylmethyl)-9-(4-fluorobenzyl)-5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine;

5-(cyclobutylmethyl)-9-(4-fluorobenzyl)-5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine;

5-[(2S)-azetidin-2-ylmethyl]-9-(4-fluorobenzyl)-5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine;

5-(azetidin-3-ylmethyl)-9-(4-fluorobenzyl)-5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine;

[5-(cyclopropylmethyl)-6,7,7a,8,10,11-hexahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepin-9(5H)-yl](pyridin-3-yl)methanone; and

2-[2-(3-benzyl-2,3,4,4a,5,6-hexahydropyrazino[1,2-a][1,5]benzodiazepin-7(1H)-yl)-2-oxoethyl]pyridazin-3(2H)-one.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030137/0222 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2011
From: BUNNELLE, WILLIAM H.; SCANIO, MARC; BREWER, JASON T.; WANG, YING; AKRITOPOULOU-ZANZE, IRINI
To: ABBOTT LABORATORIES
Reel/Frame 026691/0980 →